ENLIVEN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.89 USD | -0.04% |
|
-4.62% | +65.39% |
| May. 20 | Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing | MT |
| May. 14 | Enliven Therapeutics Q1 Loss Narrows | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 570.4 | 1,077 | - | - |
| Enterprise Value (EV) 1 | 570.4 | 914.3 | 1,031 | 829 |
| P/E ratio | -6.89 x | -9.94 x | -8.12 x | -6.98 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | 43,067 x | 43,067 x |
| EV / Revenue | - | - | 41,227 x | 33,160 x |
| EV / EBITDA | -6.83 x | -7.62 x | -6.38 x | -3.95 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 41,212 | 47,037 | - | - |
| Reference price 2 | 13.84 | 22.89 | 22.89 | 22.89 |
| Announcement Date | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 0.025 | 0.025 |
| EBITDA 1 | - | - | -83.53 | -120 | -161.5 | -209.9 |
| EBIT 1 | - | -38.79 | -83.53 | -115.7 | -142.1 | -177.3 |
| Operating Margin | - | - | - | - | -568,225.32% | -709,084% |
| Earnings before Tax (EBT) 1 | - | -37.66 | -71.58 | -103.2 | -130.5 | -168.5 |
| Net income 1 | -24.74 | -37.66 | -71.58 | -103.2 | -130.5 | -168.5 |
| Net margin | - | - | - | - | -521,854.68% | -673,905.32% |
| EPS 2 | -3.170 | -3.560 | -2.010 | -2.302 | -2.820 | -3.280 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/10/22 | 3/21/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -16.42 | -20.13 | -24.25 | -22.73 | -25.99 | -28.26 | -30.5 | -30.96 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -14.72 | -16.72 | -20.77 | -19.37 | -22.74 | -26.09 | -27.8 | -29.15 |
| Net income 1 | -14.72 | -16.72 | -20.77 | -19.37 | -22.74 | -26.09 | -27.8 | -29.15 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -0.8000 | -0.4100 | -0.5100 | -0.4700 | -0.5400 | -0.5675 | -0.6200 | -0.6300 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 5/11/23 | 8/10/23 | 11/9/23 | 3/14/24 | 5/14/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 162 | 46 | 248 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | - | 0.72 | 0.9 | 1.13 |
| Capex / Sales | - | - | - | - | 3,580% | 4,504% |
| Announcement Date | 11/10/22 | 3/21/23 | 3/14/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
22.89
USD
Average target price
34.67
USD
Spread / Average Target
+51.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +65.39% | 1.08B | |
| +9.99% | 115B | |
| +12.01% | 106B | |
| -3.07% | 24.69B | |
| -1.08% | 21.97B | |
| -5.24% | 19.27B | |
| -6.90% | 17.56B | |
| -39.36% | 17.32B | |
| +5.82% | 14.03B | |
| +33.05% | 12.13B |
- Stock Market
- Equities
- ELVN Stock
- Financials Enliven Therapeutics, Inc.
